R Pharm-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:R Pharm - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011884
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ロシア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
R Pharm is a pharmaceutical company that offers drug development and manufacturing. The company offers finished dosage forms, active pharmaceutical ingredients (api) and biotechnological substances. It provides products in therapeutic areas of oncology, hematology, immune diseases, antibiotics, antivirals, neurology, cardiology, multiple sclerosis, hemophilia and diabetes, among others. R Pharm offers supply of medicinal products and laboratory equipment for the hospitals, federal medical research centers, clinical hospitals, and regional curative and preventive care institutions in Russia. The company owns and operates manufacturing sites at Yaroslavl and Kostroma regions. It operates in Russia, the US, Turkey, and Germany among others. R-Pharm is headquartered in Moscow, Russia.

R Pharm – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
R Pharm, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
R Pharm, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
R Pharm, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
R Pharm, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
R Pharm, Medical Devices Deals, 2011 to YTD 2017 10
R Pharm, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
R Pharm, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
R-Pharm US Acquires Rights to IXEMPRA from Bristol-Myers Squibb 12
R-Pharm Acquires Production Plant in Illertissen, Germany from Pfizer 13
Partnerships 15
Midatech Pharma US Enters into Co-Marketing Agreement with R-Pharm US 15
Ilyang Pharma Enters into Agreement with R-Pharm for Supect 16
R-Pharm Enters into Research Agreement with Nagoya University 17
Scynexis Enters Into Co-Marketing Agreement With R-Pharm For SCY-078 18
R-Pharm Forms Joint Venture 19
R-Pharm Enters Into Co-Marketing Agreement With Boryung Pharma For Kanarb 20
Licensing Agreements 21
R-Pharm Enters into Licensing Agreement with Camurus 21
TaiGen Biotech Enters Into Licensing Agreement With R-Pharm For Nemonoxacin 22
Bristol-Myers Squibb Enters into Licensing Agreement with R-Pharm 23
R-Pharm Enters into Licensing Agreement with Kyorin Pharma for Imidafenacin 24
Paion Extends Licensing Agreement with R-Pharm for Remimazolam for MENA Region 25
Paion Extends Licensing Agreement With R-Pharm For Remimazolam 26
Paion Enters Into Licensing Agreement With R-Pharm For Remimazolam 27
Amgen Enters Into Licensing Agreement With R-Pharm 28
UCB Enters Into Licensing Agreement With R-Pharm For Olokizumab 29
Theravance Enters Into Licensing Agreement With R-Pharm For TD-1792 And Telavancin 30
R-Pharm Enters into Licensing Agreement with Eli Lilly 31
R-Pharm Enters Into Licensing Agreement With Merck For Narlaprevir 32
Equity Offering 33
R-Pharm Invests USD136 Million in TR-Pharma 33
Acquisition 34
R-Pharm to Acquire 51% Stake in SIA International 34
R Pharm – Key Competitors 35
R Pharm – Key Employees 36
R Pharm – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Joint Venture 38
Recent Developments 39
Product News 39
Jul 12, 2016: R-Pharm Group Completes Development of Drug for Treatment of Epilepsy 39
03/23/2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir 40
Clinical Trials 41
Mar 23, 2016: Turkish signature on the biomolecules study – Hurriyet 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
R Pharm, Pharmaceuticals & Healthcare, Key Facts 2
R Pharm, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
R Pharm, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
R Pharm, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
R Pharm, Deals By Therapy Area, 2011 to YTD 2017 9
R Pharm, Medical Devices Deals, 2011 to YTD 2017 10
R Pharm, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
R-Pharm US Acquires Rights to IXEMPRA from Bristol-Myers Squibb 12
R-Pharm Acquires Production Plant in Illertissen, Germany from Pfizer 13
Midatech Pharma US Enters into Co-Marketing Agreement with R-Pharm US 15
Ilyang Pharma Enters into Agreement with R-Pharm for Supect 16
R-Pharm Enters into Research Agreement with Nagoya University 17
Scynexis Enters Into Co-Marketing Agreement With R-Pharm For SCY-078 18
R-Pharm Forms Joint Venture 19
R-Pharm Enters Into Co-Marketing Agreement With Boryung Pharma For Kanarb 20
R-Pharm Enters into Licensing Agreement with Camurus 21
TaiGen Biotech Enters Into Licensing Agreement With R-Pharm For Nemonoxacin 22
Bristol-Myers Squibb Enters into Licensing Agreement with R-Pharm 23
R-Pharm Enters into Licensing Agreement with Kyorin Pharma for Imidafenacin 24
Paion Extends Licensing Agreement with R-Pharm for Remimazolam for MENA Region 25
Paion Extends Licensing Agreement With R-Pharm For Remimazolam 26
Paion Enters Into Licensing Agreement With R-Pharm For Remimazolam 27
Amgen Enters Into Licensing Agreement With R-Pharm 28
UCB Enters Into Licensing Agreement With R-Pharm For Olokizumab 29
Theravance Enters Into Licensing Agreement With R-Pharm For TD-1792 And Telavancin 30
R-Pharm Enters into Licensing Agreement with Eli Lilly 31
R-Pharm Enters Into Licensing Agreement With Merck For Narlaprevir 32
R-Pharm Invests USD136 Million in TR-Pharma 33
R-Pharm to Acquire 51% Stake in SIA International 34
R Pharm, Key Competitors 35
R Pharm, Key Employees 36
R Pharm, Other Locations 37
R Pharm, Subsidiaries 37
R Pharm, Joint Venture 38

★海外企業調査レポート[R Pharm-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Valmet Corp (VALMT):企業の財務・戦略的SWOT分析
    Valmet Corp (VALMT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Parex Resources Inc (PXT):石油・ガス:M&Aディール及び事業提携情報
    Summary Parex Resources Inc (Parex) is an oil and gas exploration and development company that acquires, explores, develops and produces crude oil and natural gas in South America and the Caribbean. The company holds interests in land base of 1.7 million gross acres over 22 blocks in Colombia's Llan …
  • Cineworld Group Plc:企業の戦略・SWOT・財務分析
    Cineworld Group Plc - Strategy, SWOT and Corporate Finance Report Summary Cineworld Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • BioGaia AB (BIOG B):製薬・医療:M&Aディール及び事業提携情報
    Summary BioGaia AB (BioGaia) is a biopharmaceutical company, which develops, markets and sells probiotic products. The company sells its probiotic food supplements and oral health products in various dosage forms including drops, lozenges, tablets, chewable tablets, oral rehydration salts (ORS), str …
  • LIXIL Group Corporation:企業の戦略・SWOT・財務情報
    LIXIL Group Corporation - Strategy, SWOT and Corporate Finance Report Summary LIXIL Group Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Disproquima S.A.:戦略・SWOT・企業財務分析
    Disproquima S.A. - Strategy, SWOT and Corporate Finance Report Summary Disproquima S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Holloway Lodging Corporation:戦略・SWOT・企業財務分析
    Holloway Lodging Corporation - Strategy, SWOT and Corporate Finance Report Summary Holloway Lodging Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Ross Offshore AS:石油・ガス:M&Aディール及び事業提携情報
    Summary Ross Offshore AS (Ross Offshore) is an oilfield service provider that provides project management and consultancy services. The company provides drilling and well, late life operation, subsurface, ross operations, HSEQ, consultancy services, and others. It offers late life operation services …
  • Becton, Dickinson:戦略・SWOT・企業財務分析
    Becton, Dickinson - Strategy, SWOT and Corporate Finance Report Summary Becton, Dickinson - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • China Southern Power Grid Co Ltd:電力:M&Aディール及び事業提携情報
    Summary China Southern Power Grid Co Ltd (CSG) is a power company that invests in construction, operations and management of the power grids. The company concentrates on developing regional power network, managing power dispatching and transaction center, administering regional power market, and dis …
  • Husky Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Husky Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Husky Energy Inc (Husky) is an integrated energy company. It operates across the oil and gas value chain. Its upstream operations include the exploration, development and production of crude oil, bi …
  • BASF India Ltd (BASF):企業の財務・戦略的SWOT分析
    Summary BASF India Ltd (BASF) a subsidiary of BASF SE is a chemical company that manufactures and distributes specialty chemicals, performance products, plastics and crop protection products. The company’s chemical products include intermediates, monomers and petrochemicals. Its performance products …
  • Full House Resorts, Inc.:企業の戦略・SWOT・財務情報
    Full House Resorts, Inc. - Strategy, SWOT and Corporate Finance Report Summary Full House Resorts, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Capitol Health Ltd (CAJ):企業の財務・戦略的SWOT分析
    Summary Capitol Health Ltd (Capitol Health) is a diagnostic imaging service provider. The company offers services such as bone densitomety, computer tomography, cone beam CT, CT angiography, doppler, echocardiography, fluoroscopy, general X-ray, magnetic resonance imaging, mammography, nuclear medic …
  • SunOpta Inc.:企業の戦略・SWOT・財務情報
    SunOpta Inc. - Strategy, SWOT and Corporate Finance Report Summary SunOpta Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Grand Haven Board of Light and Power:企業の戦略的SWOT分析
    Grand Haven Board of Light and Power - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Streamline Health Solutions Inc (STRM):医療機器:M&Aディール及び事業提携情報
    Summary Streamline Health Solutions Inc (Streamline Health) is a medical technology company that offers patient engagement and SaaS-based solutions. The company provides solutions including HIM, patient engagement, patient care, coding and CDI, and financial management solutions. It offers its patie …
  • Bank Hapoalim BM:戦略・SWOT・企業財務分析
    Bank Hapoalim BM - Strategy, SWOT and Corporate Finance Report Summary Bank Hapoalim BM - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Osaka Gas Co., Ltd.:戦略・SWOT・企業財務分析
    Osaka Gas Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Osaka Gas Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Chiesi USA Inc-製薬・医療分野:企業M&A・提携分析
    Summary Chiesi USA Inc (Chiesi USA), a specialty pharmaceutical company, is a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A. The company researches, develops, produces and commercializes innovative products in the areas such as cardiovascular, respiratory, neonatology, rare disease and specia …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆